JMP Securities Reiterates Market Outperform on Cytokinetics, Maintains $71 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler has reiterated a Market Outperform rating on Cytokinetics (NASDAQ:CYTK) and maintained a $71 price target.
October 09, 2023 | 1:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities has reiterated a Market Outperform rating on Cytokinetics and maintained a $71 price target.
The reiteration of a Market Outperform rating and a maintained price target by JMP Securities indicates a positive outlook for Cytokinetics. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100